Faricimab

Faricimab (INN[1]) is a bispecific monoclonal antibody that is being investigated for diabetic macular edema.

Faricimab
Monoclonal antibody
Type?
SourceHumanized
TargetVEGF-A, angiopoietin 2
Clinical data
Other namesRO6867461
ATC code
  • none
Identifiers
CAS Number
UNII
KEGG

This drug is being developed by Hoffmann-La Roche. As of 2018, faricimab is undergoing Phase III trials.

References


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.